CBPO [China Biologic Products] 8-K: (Original Filing)

[FOR RELEASE October 11, 2016 China Biologic Receives CFDA Clinical Trial Approval for Human Antithrombin III BEIJING, China – October 11, 2016 – ATIII is intended to treat hereditary and acquired ATIII deficiency in connection with surgical or obstetrical procedures, and to treat thromboembolism. No]

By | 2016-10-11T14:44:06+00:00 October 11th, 2016|Categories: CBPO, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

CBPO [China Biologic Products] 8-K: FOR RELEASE October 11, 2016 China Biologic Receives

[FOR RELEASE October 11, 2016 China Biologic Receives CFDA Clinical Trial Approval for Human Antithrombin III BEIJING, China – October 11, 2016 – ATIII is intended to treat hereditary and acquired ATIII deficiency in connection with surgical or obstetrical procedures, and to treat thromboembolism. No]

By | 2016-10-11T14:44:59+00:00 October 11th, 2016|Categories: CBPO, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More
Skip to toolbar